TREATMENT FOR ALL – HELP SUPPORT DAA TREATMENTS FOR EVERYONE WITH HEP C
New Direct Acting Anti-viral treatments are available on the Pharmaceutical Benefits Scheme (PBS), but complex treatment regimens for different genotypes may limit the capacity of GPs to treat everyone with hepatitis C. Also interferon free treatment is still not available for genotypes 4, 5 and 6.
The Pharmaceutical Benefits Advisory Committee (PBAC) will consider whether the following new combination treatments for hep C should be made available on the PBS to Australians living with hep C.
Epclusa simplifies treatment by potentially eliminating the need for genotype testing as it is active against all genotypes. It is especially useful for people whose hep C may be resistant to previous treatments.
Harvoni is being considered for patients with decompensated cirrhosis, and for treatment-naïve patients with HCV genotype 3.
Technivie is being considered for patients with genotype 4 chronic HCV infection.
Submissions close 5 October 2016, so time is tight. Click here to download the submission guide and follow the link to make an online submission.